Vnitr Lek 2013, 59(4):296-300

Oxidative stress in patients after kidney transplantation

J. Vostálová1, A. Galandáková1,*, P. Štrebl2, J. Zadražil2
1 Ústav lékařské chemie a biochemie Lékařské fakulty UP Olomouc, přednostka prof. RNDr. Jitka Ulrichová, CSc.
2 III. interní nefrologická, revmatologická a endokrinologická klinika Lékařské fakulty UP a FN Olomouc, přednosta prof. MUDr. Josef Zadražil, CSc.

Successfull kidney transplantation (KT) leads not only to normalization of renal excretory function, but also to modification of the metabolic and endocrine kidney function. The most common cause of morbidity and mortality in patients after KT are cardiovascular diseases which development is also associated with oxidative stress (OS). KT and the post-transplantation period are associated with increased OS that could gradually decrease. Some immunosuppressive drugs also contribute to increase of OS, especially compounds from a group of calcineurin inhibitors and thus indirectly contribute to increased risk of cardiovascular complications.

Keywords: oxidative stress; renal transplantation; ischemia, reperfusion injury; immunosuppressive agents

Received: November 16, 2011; Accepted: February 21, 2013; Published: April 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vostálová J, Galandáková A, Štrebl P, Zadražil J. Oxidative stress in patients after kidney transplantation. Vnitr Lek. 2013;59(4):296-300.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Viklický O et al. Transplantace ledviny v klinické praxi. Praha: Grada Publishing 2008.
    2. Viklický O. Kardiovaskulární onemocnění a jejich rizikové faktory po transplantaci ledviny. Postgraduální medicína 2008; 9: 1008-1011.
    3. Liefeldt L, Budde K. Risk factors for cardiovascular disease in renal transplant recipients and strategies to minimize risk. Transplant International. European Society for Organ Transplantation 2010; 23: 1191-1204. Go to original source... Go to PubMed...
    4. Roberts MA, Hare DL, Ratnaike S et al. Cardiovascular biomarkers in CKD: pathophysiology and implications for clinical management of cardiac disease. Am J Kidney Dis 2006; 48: 341-360. Go to original source... Go to PubMed...
    5. Pita-Fernandez S, Pertega-Diaz S, Valdes-Canedo F et al. Incidence of cardiovascular events after kidney transplantation and cardiovascular risk scores: study protocol. BMC Cardiovasc Disord. 2011; 11: 2. Go to original source... Go to PubMed...
    6. Vostálová J, Galandáková A, Štrebl P et al. Oxidační stres u pacientů s onemocnění ledvin. Vnitř Lék 2012; 58: 202-207. Go to PubMed...
    7. Eltzschig HK, Eckle T. Ischemia and reperfusion-from mechanism to translation. Nat Med 2011; 17: 1391-1401. Go to original source... Go to PubMed...
    8. Makropoulos W, Kocher K, Heintz B et al. Urinary thymidine glycol as a biomarker for oxidative stress after kidney transplantation. Ren Fail 2000; 22: 499-510. Go to original source... Go to PubMed...
    9. Biernacki M, Bigda J, Jankowski K et al. Increased serum levels of markers of oxidative stress during kidney transplantation. Transplant Proc 2002; 34: 544-545. Go to original source... Go to PubMed...
    10. Araujo M, Welch WJ. Oxidative stress and nitric oxide in kidney function. Curr Opin Nephrol Hypertens 2006; 15: 72-77. Go to original source... Go to PubMed...
    11. Snoeijs MG, van Heurn LW, Buurman WA. Biological modulation of renal ischemia-reperfusion injury. Curr Opin Organ Transplant 2010; 15: 190-199. Go to original source... Go to PubMed...
    12. Dołęgowska B, Błogowski W, Domański L. Clinical evidence of the association between serum perioperative changes in xanthine metabolizing enzymes activity and early post-transplant kidney allograft function. J Am Coll Surg 2010; 211: 587-595. Go to original source... Go to PubMed...
    13. Yamakura F, Kawasaki H. Post-translational modifications of superoxide dismutase. Biochim Biophys Acta 2010; 1804: 318-325. Go to original source... Go to PubMed...
    14. Perico N, Cattaneo D, Sayegh MH et al. Delayed graft function in kidney transplantation. Lancet 2004; 364: 1814-1827. Go to original source... Go to PubMed...
    15. Chatterjee PK. Novel pharmacological approaches to the treatment of renal ischemia-reperfusion injury: a comprehensive review. Naunyn Schmiedebergs Arch Pharmacol 2007; 376: 1-43. Go to original source... Go to PubMed...
    16. Chatauret N, Thuillier R, Hauet T. Preservation strategies to reduce ischemic injury in kidney transplantation: pharmacological and genetic approaches. Curr Opin Organ Transplant 2011; 16: 180-187. Go to original source... Go to PubMed...
    17. Nankivell BJ, Kuypers DR. Diagnosis and prevention of chronic kidney allograft loss. Lancet 2011; 378: 1428-1437. Go to original source... Go to PubMed...
    18. Simmons EM, Langone A, Sezer MT et al. Effect of renal transplantation on biomarkers of inflammation and oxidative stress in end-stage renal disease patients. Transplantation 2005; 79: 914-919. Go to original source... Go to PubMed...
    19. Zahmatkesh M, Kadkhodaee M, Mahdavi-Mazdeh M et al. Oxidative stress status in renal transplant recipients. Exp Clin Transplant 2010; 8: 38-44.
    20. Joo DJ, Huh KH, Cho Y et al. Change in serum lipid peroxide as an oxidative stress marker and its effects on kidney function after successful kidney transplantation. Transplant Proc 2010; 42: 729-732. Go to original source... Go to PubMed...
    21. Vural A, Yilmaz MI, Caglar K et al. Assessment of oxidative stress in the early posttransplant period: comparison of cyclosporine A and tacrolimus-based regimens. Am J Nephrol 2005; 25: 250-255. Go to original source... Go to PubMed...
    22. Moreno JM, Ruiz MC, Ruiz N et al. Modulation factors of oxidative status in stable renal transplantation. Transplant Proc 2005; 37: 1428-1430. Go to original source... Go to PubMed...
    23. Zadražil J, Horák P, Štrebl P et al. In vivo oxidized low-density lipoprotein (ox-LDL) aopp and tas after kidney transplantation: a prospective, randomized one year study comparing cyclosporine A and tacrolimus based regiments. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2012; 156: 14-20. Go to original source... Go to PubMed...
    24. Vostálová J, Galandáková A, Svobodová AR et al. Time-course evaluation of oxidative stress-related biomarkers after renal transplantation. Ren Fail 2012; 34: 413-419. Go to original source... Go to PubMed...
    25. Vostálová J, Galandáková A, Svobodová AR et al. Stabilization of oxidative stress 1 year after kidney transplantation: effect of calcineurin immunosuppressives. Ren Fail 2012; 34: 952-959. Go to original source... Go to PubMed...
    26. Emre H, Keles M, Yildirim S et al. Comparison of the oxidant-antioxidant parameters and sialic acid levels in renal transplant patients and peritoneal dialysis patients. Transplant Proc 2011; 43: 809-812. Go to original source... Go to PubMed...
    27. Cueto-Manzano AM, Morales-Buenrostro LE, González-Espinoza L et al. Markers of inflammation before and after renal transplantation. Transplantation 2005; 80: 47-51. Go to original source... Go to PubMed...
    28. Cristol JP, Vela C, Maggi MF et al. Oxidative stress and lipid abnormalities in renal transplant recipients with or without chronic rejection. Transplantation 1998; 65: 1322-1328. Go to original source... Go to PubMed...
    29. Lojek A, Černý J, Němec P et al. Phagocyte-induced oxidative stress in patients with haemodialysis treatment and organ transplantation. Biofactors 1998; 8: 165-168. Go to original source... Go to PubMed...
    30. Ramezani M, Nazemian F, Shamsara J et al. Effect of Omega-3 Fatty Acids on Plasma Level of 8-Isoprostane in Kidney Transplant Patients. J Ren Nutr 2010; 17: 196-199. Go to original source...
    31. Haririan A, Metireddy M, Cangro C et al. Association of Serum Uric Acid With Graft Survival After Kidney Transplantation: A Time-Varying Analysis. Am J Transplant 2011; 11: 1943-1150. Go to original source... Go to PubMed...
    32. Zachara BA, Gromadzińska J, Wasowicz W et al. Red blood cell and plasma glutathione peroxidase activities and selenium concentration in patients with chronic kidney disease: a review. Acta Biochim Pol 2006; 53: 663-677. Go to original source... Go to PubMed...
    33. Cantarovich D, Vistoli F, Soulillou JP. Immunosuppression minimization in kidney transplantation. Front Biosci 2008; 13: 1413-1432. Go to original source... Go to PubMed...
    34. Viklický O. Imunosupresivní terapie. Postgraduální medicina 2008; 9: 996-1006.
    35. Walker RJ, Lazzaro VA, Duggin GG et al. Evidence that alterations in renal metabolism and lipid peroxidation may contribute to cyclosporine nephrotoxicity. Transplantation 1990; 50: 487-492. Go to original source... Go to PubMed...
    36. Ahmed SS, Strobel HW, Napoli KL et al. Adrenochrome reaction implicates oxygen radicals in metabolism of cyclosporine A and FK-506 in rat and human liver microsomes. J Pharmacol Exp Ther 1993; 265: 1047-1054. Go to PubMed...
    37. Krauskopf A, Buetler TM, Nguyen NS et al. Cyclosporin A-induced free radical generation is not mediated by cytochrome P-450. Br J Pharmacol 2002; 135: 977-986. Go to original source... Go to PubMed...
    38. Calo LA, Davis PA, Giacon B et al. Oxidative stress in kidney transplant patients with calcineurin inhibitor-induced hypertesion: Effect of ramipril. J Cardiovasc Pharmacol 2002; 40: 625-631. Go to original source... Go to PubMed...
    39. Varghese Z, Fernando RL, Turakhia G et al. Oxidizability of Low-Density Lipoproteins From Neoral and Tacrolimus-Treated Renal Transplant Patients. Transplant Proc 1998; 30: 2043-2046. Go to original source... Go to PubMed...
    40. Varghese Z, Fernando RL, Turakhia G et al. Calcineurin inhibitors enhance low-density lipoprotein oxidation in transplant patients. Kidney Int Suppl 1999; 71: S137-S140. Go to original source... Go to PubMed...
    41. Cofan F, Cofan M, Campos B et al. Effect of calcineurin inhibitors on low-density lipoprotein oxidation. Transplant Proc 2005; 37: 3791-3793. Go to original source... Go to PubMed...
    42. Martínez Castelao A, Ramos R, Serón D et al. Effect of cyclosporin and tacrolimus on lipoprotein oxidation after renal transplantation. Nekrologia 2002; 22: 364-369.
    43. Perrea DN, Moulakakis KG, Poulakou MV et al. Correlation between oxidative stress and immunosuppressive therapy in renal transplant recipients with an uneventful postoperative course and stable renal function. Int Urol Nephrol 2006; 38: 343-348. Go to original source... Go to PubMed...
    44. Morena M, Vela C, Garrigue V et al. Low-Density Lipoprotein Composition and Oxidation Are Not Influenced by Calcineurin Inhibitors in Renal Transplant Patients. Transplant Proc 2000; 32: 2785-2786. Go to original source... Go to PubMed...
    45. Štrebl P, Horčička jr. V, Krejči K et al. Oxidative stress after kidney transplantation: The role of immunosuppression. Dial Transplant 2010; 39: 391-394. Go to original source...
    46. Zadražil J, Štrebl P, Krejčí K et al. Effect of different calcineurin inhibitors on AOPP and TAS after kidney transplantation. Clin Biochem 2010; 43: 559-565. Go to original source... Go to PubMed...
    47. Calò LA, Dall'Amico R, Pagnin E et al. Oxidative stress and post-transplant hypertension in pediatric kidney-transplanted patients. J Pediatr 2006; 149: 53-57. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.